SEC Form SC 13G/A filed by REGENXBIO Inc. (Amendment)

$RGNX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $RGNX alert in real time by email
SC 13G/A 1 REGENXBIO_Inc.htm FILING REGENXBIO INC. Schedule 13G


 
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G
 
 
Under the Securities Exchange Act of 1934
(Amendment No. 04)*
 
REGENXBIO Inc. 

(Name of Issuer)
 
Common Stock, par value $0.0001 per share

(Title of Class of Securities)
 
75901B107

(CUSIP Number)
 
December 29, 2023

(Date of Event Which Requires Filing of this Statement)
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
     x  Rule 13d-1(b)
 
     o  Rule 13d-1(c)
 
     o  Rule 13d-1(d)
 
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 


 
 

 
 
CUSIP No.  75901B107            
 
           
1   NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
  JPMORGAN CHASE & CO.

13-2624428
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



  (a)   o
  (b)   o
     
3   SEC USE ONLY
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
   
  3,530,736
     
6   SHARED VOTING POWER
   
  0
     
7   SOLE DISPOSITIVE POWER
   
  3,932,416
     
8   SHARED DISPOSITIVE POWER
   
  105
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  3,932,521
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  8.9 %
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  HC
 

FOOTNOTES
   
 
 
 

 
 
Item 1.


 
(a)
Name of Issuer
 
 
REGENXBIO Inc.


 
(b)
Address of Issuer’s Principal Executive Offices
 
 
9804 Medical Center Drive,
Rockville, MD 20850


Item 2.


 
(a)
Name of Person Filing
 
 
JPMORGAN CHASE & CO.


 
(b)
Address of Principal Business Office or, if none, Residence
 
 
383 Madison Avenue
New York, NY 10179


 
(c)
Citizenship
 
 
Delaware


 
(d)
Title of Class of Securities
 
 
Common Stock, par value $0.0001 per share


 
(e)
CUSIP Number
 
 
75901B107


 
Item 3.
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


 
(a)
o
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


 
(b)
o
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


 
(c)
o
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


 
(d)
o
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


 
(e)
o
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


 
(f)
o
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


 
(g)
x
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


 
(h)
o
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


 
(i)
o
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


 
(j)
o
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


 
(k)
o
A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


 
 
 

 
 
Item 4.
Ownership.
 
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


 
(a)
Amount beneficially owned: 3,932,521


 
(b)
Percent of class: 8.9 %


 
(c)
Number of shares as to which the person has:


 
(i)
Sole power to vote or to direct the vote: 3,530,736


 
(ii)
Shared power to vote or to direct the vote: 0


 
(iii)
Sole power to dispose or to direct the disposition of: 3,932,416


 
(iv)
Shared power to dispose or to direct the disposition of: 105


Item 5.
Ownership of Five Percent or Less of a Class
 
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
 
 
 
Item 6.
Ownership of More than Five Percent on Behalf of Another Person.
 
Not Applicable
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
 
J.P. Morgan Trust Company of Delaware
JPMorgan Chase Bank, National Association
J.P. Morgan Investment Management Inc.
J.P. Morgan Private Wealth Advisors LLC
 
Item 8.
Identification and Classification of Members of the Group
 
Not Applicable
 
Item 9.
Notice of Dissolution of Group
 
Not Applicable
 
 
 

 
 
 
Item 10.
Certification
   
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
 
 


SIGNATURE


After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
  JPMORGAN CHASE & CO.

 
       
Date: January 25, 2024
By:
/s/  Rachel Tsvaygoft  
    Name: Rachel Tsvaygoft  
    Title:  Vice President  
       
 
Footnotes:


Attention:
Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
 
 



Get the next $RGNX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RGNX

DatePrice TargetRatingAnalyst
2/11/2025$38.00 → $14.00Buy → Neutral
Goldman
2/7/2025$27.00Outperform
Raymond James
11/15/2024$22.00Overweight
Morgan Stanley
10/10/2024$18.00Outperform
Raymond James
6/7/2024$38.00Buy
Goldman
3/11/2024$36.00Buy
H.C. Wainwright
3/8/2024$20.00 → $35.00Sector Perform → Outperform
RBC Capital Mkts
3/6/2024$37.00Market Perform → Outperform
Leerink Partners
More analyst ratings

$RGNX
Press Releases

Fastest customizable press release news feed in the world

See more
  • REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

    Positive biomarker data in patient aged 1-3 add to consistent, robust microdystrophin and transduction levels across all treated ages Patient aged 3 years at dosing had expression level at 122.3% compared to controlWith a differentiated novel construct and proactive short course immune modulation regimen, RGX-202 continues to demonstrate encouraging safety profile with no SAEs or AESIs Phase III portion of AFFINITY DUCHENNE® trial enrolling ambulatory patients aged 1 and above, on track for BLA submission mid-2026ROCKVILLE, Md., March 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the A

    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

    Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) submitted and on track for potential FDA approval 2H 2025; strategic partnership with Nippon Shinyaku aims to expand potential access and commercial opportunity in MPS II and MPS IPivotal trial of RGX-202 for Duchenne Muscular Dystrophy progressing rapidly; enrollment completion expected in 2025 with BLA filing in mid-2026 AbbVie-partnered retinal franchise continues advancing; pivotal data evaluating the safety and efficacy of the subretinal delivery of surabgene lomparvovec (ABBV-RGX-314) in patients with wet age-related macular degeneration are expected in 2026 and planning of diabetic retinopathy pivotal study c

    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

    ROCKVILLE, Md., March 10, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced new interim biomarker data from the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202 for the treatment of Duchenne muscular dystrophy will be presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place in Dallas, TX, March 16-19, 2025. Title: RGX-202, an investigational gene therapy for the treatment of Duchenne Muscular Dystrophy: Interim clinical data (O75)Session: Clinical TrialsDate/Time: Wednesday, March 19, 2025; 8:15 a.m. CTPresenter: Carolina Tesi Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Childre

    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$RGNX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RGNX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RGNX
SEC Filings

See more

$RGNX
Leadership Updates

Live Leadership Updates

See more
  • Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    $AMTM
    $APO
    $CMA
    $CRI
    Investment Managers
    Finance
    Major Banks
    Apparel
  • REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

    Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programsVit Vasista steps down following more than 15 years at the CompanyROCKVILLE, Md., Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. A veteran finance executive and operating partner in the biotechnology industry, Mr. Chan has held key roles in raising capital, business development transactions and operations for nearly 20 years.  "We are excited to welcome Mitchell at this exciting time for REGENXBIO," said Curran Simpson, President and

    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • REGENXBIO Announces Leadership Transition

    Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as RE

    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$RGNX
Financials

Live finance-specific insights

See more
  • REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

    ROCKVILLE, Md., Feb. 26, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a leading

    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

    ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Wednesday, November 6, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-s

    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

    ROCKVILLE, Md., July 25, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2024, and recent operational highlights. To access the live call by phone, dial (646) 307-1963 (domestic) or (800) 715-9871 (international) and enter the passcode 4849384. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call. Those who plan on participating are advised to join 15 minutes prior

    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$RGNX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more